Cargando…
Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274104/ https://www.ncbi.nlm.nih.gov/pubmed/35818701 http://dx.doi.org/10.3346/jkms.2022.37.e210 |
_version_ | 1784745232519135232 |
---|---|
author | Hyun, Hakjun Choi, Min Joo Heo, Jung Yeon Seo, Yu Bin Nham, Eliel Yoon, Jin Gu Seong, Hye Noh, Ji Yun Cheong, Hee Jin Kim, Woo Joo Choi, Ju-Yeon Lee, Young Jae Lee, Hye Won Kim, Sung Soon Kim, Byoungguk Song, Joon Young |
author_facet | Hyun, Hakjun Choi, Min Joo Heo, Jung Yeon Seo, Yu Bin Nham, Eliel Yoon, Jin Gu Seong, Hye Noh, Ji Yun Cheong, Hee Jin Kim, Woo Joo Choi, Ju-Yeon Lee, Young Jae Lee, Hye Won Kim, Sung Soon Kim, Byoungguk Song, Joon Young |
author_sort | Hyun, Hakjun |
collection | PubMed |
description | BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. METHOD: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-γ enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. RESULTS: Fifty participants aged ≥ 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 ± 3.0 U/mL at 3–4 weeks, 55.7 ± 2.4 U/mL at 5–8 weeks, and 81.3 ± 2.5 U/mL at 10–12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS-CoV-2 were 164.6 ± 4.6 at 3-4 weeks, 313.9 ± 3.6 at 5–8 weeks, and 124.4 ± 2.6 at 10–12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/10(6) peripheral blood mononuclear cell was 25.0 (5.0–29.2) at baseline, 60.0 (23.3–178.3) at 5-8 weeks, and 35.0 (13.3–71.7) at 10–12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1–2, and resolved within two days. CONCLUSION: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5–8 weeks and rather decrease at 10–12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible. |
format | Online Article Text |
id | pubmed-9274104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-92741042022-07-21 Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study Hyun, Hakjun Choi, Min Joo Heo, Jung Yeon Seo, Yu Bin Nham, Eliel Yoon, Jin Gu Seong, Hye Noh, Ji Yun Cheong, Hee Jin Kim, Woo Joo Choi, Ju-Yeon Lee, Young Jae Lee, Hye Won Kim, Sung Soon Kim, Byoungguk Song, Joon Young J Korean Med Sci Original Article BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. METHOD: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-γ enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. RESULTS: Fifty participants aged ≥ 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 ± 3.0 U/mL at 3–4 weeks, 55.7 ± 2.4 U/mL at 5–8 weeks, and 81.3 ± 2.5 U/mL at 10–12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS-CoV-2 were 164.6 ± 4.6 at 3-4 weeks, 313.9 ± 3.6 at 5–8 weeks, and 124.4 ± 2.6 at 10–12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/10(6) peripheral blood mononuclear cell was 25.0 (5.0–29.2) at baseline, 60.0 (23.3–178.3) at 5-8 weeks, and 35.0 (13.3–71.7) at 10–12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1–2, and resolved within two days. CONCLUSION: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5–8 weeks and rather decrease at 10–12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible. The Korean Academy of Medical Sciences 2022-06-28 /pmc/articles/PMC9274104/ /pubmed/35818701 http://dx.doi.org/10.3346/jkms.2022.37.e210 Text en © 2022 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Hyun, Hakjun Choi, Min Joo Heo, Jung Yeon Seo, Yu Bin Nham, Eliel Yoon, Jin Gu Seong, Hye Noh, Ji Yun Cheong, Hee Jin Kim, Woo Joo Choi, Ju-Yeon Lee, Young Jae Lee, Hye Won Kim, Sung Soon Kim, Byoungguk Song, Joon Young Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study |
title | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study |
title_full | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study |
title_fullStr | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study |
title_full_unstemmed | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study |
title_short | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study |
title_sort | immunogenicity and reactogenicity of ad26.cov2.s in korean adults: a prospective cohort study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274104/ https://www.ncbi.nlm.nih.gov/pubmed/35818701 http://dx.doi.org/10.3346/jkms.2022.37.e210 |
work_keys_str_mv | AT hyunhakjun immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT choiminjoo immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT heojungyeon immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT seoyubin immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT nhameliel immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT yoonjingu immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT seonghye immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT nohjiyun immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT cheongheejin immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT kimwoojoo immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT choijuyeon immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT leeyoungjae immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT leehyewon immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT kimsungsoon immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT kimbyoungguk immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy AT songjoonyoung immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy |